Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

被引：0
作者：
Jiao Yang
Bing Zhao
Xiaoling Ling
Donghui Li
Jiuda Zhao
Yonggang Lv
Guangxi Wang
Xinlan Liu
Nanlin Li
Jin Yang
机构：
[1] The First Affiliated Hospital of Xi’an Jiaotong University,Departments of Medical Oncology
[2] The 3rd Affiliated Teaching Hospital of XinJiang Medical University (Affiliated Tumor Hospital),Breast Internal Medicine Department
[3] The First Hospital of Lanzhou University,Department of Oncology
[4] Lanzhou University,Department of Medical Oncology
[5] Shaanxi Provincial People’s Hospital,Department of Thyroid Breast Surgery
[6] Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University,Department of Oncology
[7] the Affiliated Hospital of Northwest University,Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital
[8] General Hospital of Ningxia Medical University,Department of Medical Oncology
[9] The Fourth Military Medical University,undefined
[10] Shaanxi Provincial Tumor Hospital,undefined
来源：
BMC Cancer | / 23卷
关键词：
Metastatic breast cancer; CDK4/6 inhibitor; Endocrine therapy; Real-world;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 302 条
[1]  
Waks AG(2019)Breast Cancer Treatment: a review JAMA 321 288-300
[2]  
Winer EP(2020)Overcoming endocrine resistance in breast Cancer Cancer Cell 37 496-513
[3]  
Hanker AB(2016)Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast Cancer: a review of preclinical and clinical data Clin Breast Cancer 16 8-17
[4]  
Sudhan DR(2022)ABC6 Consensus: Assessment by a group of german experts Breast Care (Basel) 17 90-100
[5]  
Arteaga CL(2020)Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Cancer Network: JNCCN 18 452-78
[6]  
Vidula N(2016)Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 17 425-39
[7]  
Rugo HS(2019)Palbociclib Plus Letrozole as First-Line therapy in postmenopausal asian women with metastatic breast Cancer: results from the Phase III, Randomized PALOMA-2 study J global Oncol 5 1-19
[8]  
Luftner D(2016)Efficacy and safety of Palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 Breast cancer research: BCR 18 67-303
[9]  
Fasching PA(2017)PALOMA-3: phase III trial of Fulvestrant with or without Palbociclib in Premenopausal and Postmenopausal Women with hormone Receptor-Positive, human epidermal growth factor receptor 2-Negative metastatic breast Cancer that progressed on prior endocrine therapy-safety and efficacy in asian patients J global Oncol 3 289-7
[10]  
Haidinger R(2019)Real-world effectiveness of Palbociclib Versus Clinical Trial results in patients with Advanced/Metastatic breast Cancer that progressed on previous endocrine therapy Breast Cancer (Auckl) 13 1178223418823238-40
12345678910